Med Ed Report briefs: October 2013

Med Ed Report briefs: October 2013
Med Ed Report briefs: October 2013

Online CME continues to displace face-to-face interactions, according to a survey by three groups including Elsevier's Office of CME. Out of 801 doctors, 97% said they will do more online CME, and 40% said they will up their Virtual Course list in 2014.

In the wake of the CDC's anti-smoking “Tips” advertising blitz, an editorial by Chinese researchers in the Lancet suggested the campaign could be a model for other countries and called for more education. Tips led some 220,000 current smokers to quit and about 1.4 million others to attempt cessation, CDC said.

Non-profit CME group Southern Medical Association launched an online CME catalog on its website, sma.org, that covers topics including women's health, ethics, disaster preparedness and spirituality and medicine, among others.

Astellas is funding a three-part series, produced by CME Outfitters, on overactive bladder treatment adherence. The courses are an extension of information that was shared at May's American Urological Association's Annual Meeting. Topics include recognizing OAB ­prevalence, treatment options and patient conversations.
You must be a registered member of MMM to post a comment.

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.